CD4-directed Blocking Antibody [EPC]

540 reported adverse events

Drugs of this class: IBALIZUMAB

These side effects are most commonly reported by patients taking drugs of the CD4-directed Blocking Antibody [EPC] class:

# Side effect Count
0 PRODUCT DOSE OMISSION ISSUE 45
1 VIRAL LOAD INCREASED 45
2 DRUG INEFFECTIVE 44
3 RASH 43
4 HOSPITALISATION 36
5 FATIGUE 30
6 OFF LABEL USE 30
7 DIARRHOEA 28
8 NAUSEA 26
9 DEATH 25
See all common reactions for CD4-directed Blocking Antibody [EPC]

Drugs of the CD4-directed Blocking Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BLOOD HIV RNA 4 0.0769
1 CONGENITAL HIV INFECTION 2 0.0513
2 ANAL CANCER RECURRENT 1 0.0476
3 PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT 11 0.0126
4 T-LYMPHOCYTE COUNT DECREASED 8 0.0117
5 VIRAL LOAD INCREASED 45 0.0116
6 GENOTYPE DRUG RESISTANCE TEST POSITIVE 11 0.0107
7 DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX INFECTION 1 0.0045
8 BLOOD HIV RNA INCREASED 8 0.0044
9 CD4 LYMPHOCYTES INCREASED 1 0.0043
See all enriched reactions for CD4-directed Blocking Antibody [EPC]